CN102048841A - Lactogenic traditional Chinese medicine composition and preparation method thereof - Google Patents
Lactogenic traditional Chinese medicine composition and preparation method thereof Download PDFInfo
- Publication number
- CN102048841A CN102048841A CN200910228130XA CN200910228130A CN102048841A CN 102048841 A CN102048841 A CN 102048841A CN 200910228130X A CN200910228130X A CN 200910228130XA CN 200910228130 A CN200910228130 A CN 200910228130A CN 102048841 A CN102048841 A CN 102048841A
- Authority
- CN
- China
- Prior art keywords
- radix
- ethanol
- hour
- concentrated solution
- radix scutellariae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 66
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 230000001983 lactogenic effect Effects 0.000 title abstract description 10
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 198
- 239000013543 active substance Substances 0.000 claims description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 39
- 239000007788 liquid Substances 0.000 claims description 34
- 210000000582 semen Anatomy 0.000 claims description 34
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 21
- 238000001035 drying Methods 0.000 claims description 18
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 18
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 17
- 239000006071 cream Substances 0.000 claims description 16
- 239000006228 supernatant Substances 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 15
- 238000009413 insulation Methods 0.000 claims description 15
- 239000002244 precipitate Substances 0.000 claims description 15
- 239000002994 raw material Substances 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 12
- 239000012141 concentrate Substances 0.000 claims description 11
- 238000002481 ethanol extraction Methods 0.000 claims description 9
- 238000011084 recovery Methods 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 241000207929 Scutellaria Species 0.000 claims description 6
- 230000009471 action Effects 0.000 claims description 5
- 206010013786 Dry skin Diseases 0.000 claims description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims description 2
- 238000003916 acid precipitation Methods 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- 238000012546 transfer Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- 240000004534 Scutellaria baicalensis Species 0.000 abstract 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract 1
- 244000290970 Tetrapanax papyrifer Species 0.000 abstract 1
- 244000178320 Vaccaria pyramidata Species 0.000 abstract 1
- 235000010587 Vaccaria pyramidata Nutrition 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 45
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 239000008280 blood Substances 0.000 description 15
- 230000006651 lactation Effects 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 235000013336 milk Nutrition 0.000 description 12
- 239000008267 milk Substances 0.000 description 12
- 210000004080 milk Anatomy 0.000 description 12
- 239000008187 granular material Substances 0.000 description 11
- 208000019395 Lactation disease Diseases 0.000 description 10
- 206010042576 Suppressed lactation Diseases 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 210000005075 mammary gland Anatomy 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 235000008504 concentrate Nutrition 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 108010037528 lactotropin Proteins 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 102000003946 Prolactin Human genes 0.000 description 5
- 108010057464 Prolactin Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 229940097325 prolactin Drugs 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 210000003016 hypothalamus Anatomy 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- -1 main catharsis Substances 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 241000283956 Manis Species 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000001467 acupuncture Methods 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000035568 catharsis Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 201000002451 Overnutrition Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000037006 agalactosis Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000004567 concrete Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000003808 methanol extraction Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000019989 milk ejection Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 208000008588 molluscum contagiosum Diseases 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 235000020823 overnutrition Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000012859 sterile filling Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- ZAVXXBAIPSQJGS-UHFFFAOYSA-B tetracalcium;tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O.[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O.[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ZAVXXBAIPSQJGS-UHFFFAOYSA-B 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Abstract
The invention relates to a lactogenic traditional Chinese medicine composition and a preparation method thereof. The composition consists of radix bupleuri, radix paeoniae alba, scutellaria baicalensis, radix rhapontici, tetrapanax papyriferus, ligusticum wallichii and the seed of cowherb.
Description
Technical field
The present invention relates to a kind of field of medicaments, particularly a kind of Chinese medicine composition and preparation method thereof with galgctogogue action.
Background technology
Along with the raising of development of science and technology and people's living standard, breast feeding more and more comes into one's own; But simultaneously owing to the quickening of people's rhythm of life and the increase of life stress, the progressively trend of rising appears in the postpartum milk secretion deficiency in women especially city women.20 provinces of China (city) investigation statistics shows that suckling in 4 months puerperal rate only accounts for 44%.And a key problem that improves breastfeeding rate is to promote and maintenance wet nurse galactopoiesis.According to theory of Chinese medical science the insufficient classification diagnosis of postpartum milk secretion is come determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs.At present mainly based on deficient qi and blood and stagnation of QI due to depression of the liver amphitypy., puerpera overnutrition increasing owing to the productive rate of cutting open the belly at present and reason such as unbalanced, the puerpera of qi-blood asthenia type hypogalactia is increasing.
At the clinical definite effective method that there is no of lactogenic treatment, mainly contain dietetic therapy among the people, hot compress, acupuncture, massage, Chinese medicinal formulae, the auxiliary methods such as breast, milk ejection of inhaling of armarium at present.Though dietetic therapy among the people is more general, uncertain therapeutic efficacy is fixed, lacks the scientific research support, and easily causes allergic reaction.Acupuncture, massage, armarium complementary therapy mostly are assosting effect, unsuitable conventional the use.
In Drug therapy, doctor trained in Western medicine lacks medicine effective and with strong points at treatment puerperal hypogalactia this respect, and often side effect is bigger, thus clinical application at present mainly based on Chinese medicinal formulae, decoction is treated, patient takes medicine and agonizes, compliance is bad.In addition, as the lactogenesis electuary, the stimulating milk secretion spring loose to wait in the prescription and all adds the animal drug Squama Manis in the domestic lactogenic Chinese patent medicine of having ratified, and Squama Manis to be national two classes treasure watches for animals, can not satisfy the demand of clinical application.Poor through the medicine stability that experiment showed, the galgctogogue action of selling on the existing market for a long time, side effect is big, and price is more expensive.
The traditional Chinese medical science is thought, married woman's milk by the life of blood instituteization, relies the operation of gas, and the change of QI and blood is given birth to and derived from the smart emblem of water paddy, depends on being received of taste, fortune.Breast belongs to positive bright stomach warp, and nipple belongs to the cloudy Liver Channel of fainting, liver storing blood, main catharsis, milk excessive rush down with discharge normal, depend on the irritability bar and reach, catharsis degree of having.The generation of hypogalactia has void that reality is arranged, and void is deficient qi and blood, the strength stagnation of QI due to depression of the liver.Puerpera's factor body weakness of the spleen and stomach or severe loss of blood when producing make deficiency of qi and blood, milk source deficiency, and agalactia can descend and cause hypogalactia; Or because of puerperal feelings will not smooth, stagnation of QI due to depression of the liver, the retardance of newborn arteries and veins, milk is stopped up and is closed not all right and cause hypogalactia.
The Semen Vaccariae promoting blood circulation to restore menstrual flow, the stimulating milk secretion detumescence.The Radix Bupleuri reconciling superficies and interior, soothing liver-QI for relieving depression.Rhizoma Chuanxiong is warm in nature, is the gas medicine in the blood, and it is strongly fragrant to go into the liver air to open of passing through, the nourishing blood and promoting blood circulation circulation of qi promoting.Radix Paeoniae Alba nourishing blood to suppress the hyperactive liver, slow middle pain relieving.Radix Scutellariae nature and flavor hardship, cold, heat clearing and damp drying, eliminating fire and detoxication.Radix Rhapontici, sweet in flavor and cold in property, be the removing toxic substances and promoting pus discharge key medicine, can sharp key with it, kind stimulating milk secretion and show, later age long with Semen Vaccariae, Squama Manis, Medulla Tetrapanacis compatibility, treat puerperal hypogalactia.Medulla Tetrapanacis, " go into positive bright stomach warp, beat in the ventilation and following milk ".Above flavour of a drug compatibility meets the QI and blood abundance, and then milk biochemistry is active, and the breast amount is abundant; The irritability bar reaches, the blood vessels tonneau, and then the milk operation is fluent.
Summary of the invention
The object of the invention is to provide a kind of Chinese medicine composition at hypogalactia, hypogalactia due to the stagnation of QI due to depression of the liver.
Another object of the present invention is to provide preparation of compositions method of the present invention.
Pharmaceutical composition of the present invention, be processed into by the raw material of following weight parts:
Radix Bupleuri 3-30 part, Radix Paeoniae Alba 3-30 part, Radix Scutellariae 2-18 part, Radix Rhapontici 3-30 part,
Medulla Tetrapanacis 2-18 part, Rhizoma Chuanxiong 3-30 part, Semen Vaccariae 5-45 part.
Compositions of the present invention, preferably be processed into by the raw material of following weight parts:
Radix Bupleuri 5-20 part, Radix Paeoniae Alba 5-20 part, Radix Scutellariae 3-12 part, Radix Rhapontici 5-20 part,
Medulla Tetrapanacis 3-12 part, Rhizoma Chuanxiong 5-20 part, Semen Vaccariae 7.5-30 part.
Compositions of the present invention, most preferably be processed into by the raw material of following weight parts:
10 parts of Radix Bupleuri, 10 parts of the Radix Paeoniae Albas, 6 parts of Radix Scutellariaes, 10 parts of Radix Rhapontici,
6 parts of Medulla Tetrapanaciss, 10 parts of Rhizoma Chuanxiongs, 15 parts of Semen Vaccariae.
In more than forming, weight is calculated with crude drug, and part is a weight portion, if with the gram is unit, more than composition can be made into a pharmaceutical preparation 5-50 preparation unit, and described preparation unit refers to, the final drug preparation of making, as make solid preparation 5-50 unit, oral liquid 5-50ml etc.
More than form the preparation that can be made into 1-6 taking dose, as tablet, make 18, each taking dose can be the 3-18 sheet, can take 1-6 time altogether.As granule, make 6 bags, take the 1-2 bag at every turn, can take 3-6 time altogether.
More than form to be by weight as proportioning, when producing, can increase or reduce according to corresponding proportion, as large-scale production can be unit with the kilogram, or be unit with the ton, small-scale production can be unit with the milligram also, weight can increase or reduce, but the constant rate of the raw medicinal herbs weight proportion between each composition.
The ratio of above weight proportion obtains through science screening, for especial patient, and as serious symptom or light disease, fat or modest patient, the proportioning of the amount of can corresponding adjustment forming increases or reduces being no more than 300%, and drug effect is constant.
Single medicinal material, especially ministerial drug and adjuvant drug in more than forming also can be replaced by the suitable Chinese medicine with identical property of medicine, and its drug effect of the Chinese medicine preparation after the replacement is constant.
Chinese medicine composition of the present invention is to process through extraction or other modes by the raw material of Chinese medicine that above-mentioned prescription is formed, and makes pharmaceutically active substance, subsequently, with this material is raw material, adds the medicine acceptable carrier when needing, and makes according to the routine techniques of galenic pharmacy.Described active substance can obtain by extracting raw material of Chinese medicine respectively, also can obtain by the co-extracted raw material of Chinese medicine, also can obtain by other modes, as: by pulverize, squeeze, calcine, grind, sieve, percolation, extraction, water are carried, alcohol extraction, ester are carried, methods such as ketone is carried, chromatography obtain, these active substances can be the material of extractum form, can be that dry extract also can be a fluid extract, make different concentration according to the different needs decision of preparation.
Pharmaceutically active substance in the Chinese medicine composition of the present invention, its shared percentage by weight in preparation can be 0.1-99.9%, all the other are the medicine acceptable carrier.Pharmaceutical composition of the present invention exists with unit dosage form, and described unit dosage form is meant the unit of preparation, as every of tablet, and capsular every capsules, every bottle of oral liquid, every bag of granule etc.
Chinese medicine composition of the present invention can be any pharmaceutically useful dosage form, and these dosage forms comprise: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, unguentum, sublimed preparation, suspensoid, powder, solution, injection, suppository, ointment, plaster, cream, spray, drop, patch.Preparation of the present invention, peroral dosage form preferably, as: capsule, tablet, oral liquid, granule, pill, powder, sublimed preparation, unguentum etc.
Chinese medicine composition of the present invention, the preparation of its oral administration can contain excipient commonly used, such as binding agent, filler, diluent, tablet agent, lubricant, disintegrating agent, coloring agent, flavoring agent and wetting agent, can carry out coating to tablet in case of necessity.
The filler that is suitable for comprises cellulose, mannitol, lactose and other similar filler.Suitable disintegrating agent comprises starch, polyvinylpyrrolidone and starch derivatives, for example sodium starch glycollate.Suitable lubricant comprises, for example magnesium stearate.The acceptable wetting agent of appropriate drug comprises sodium lauryl sulphate.
Can fill by mixing, the method that tabletting etc. are commonly used prepares solid oral composition.Mix repeatedly active substance is distributed in those compositionss of a large amount of filleies of whole use.
The form of oral liquid for example can be aqueous or oily suspensions, solution, Emulsion, syrup or elixir, perhaps can be a kind of available water before use or other suitable composite dry products of carrier.This liquid preparation can contain conventional additive, such as suspending agent, for example sorbitol, syrup, methylcellulose, gelatin, hydroxyethyl-cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenation edible fat, emulsifying agent, for example lecithin, anhydro sorbitol monooleate or arabic gum; Non-aqueous carrier (they can comprise edible oil), for example almond oil, fractionated coconut oil, such as oily ester, propylene glycol or the ethanol of the ester of glycerol; Antiseptic, for example para hydroxybenzene methyl ester or propyl p-hydroxybenzoate or sorbic acid, and if desired, can contain conventional flavouring agent or coloring agent.
For injection, the liquid unit dosage forms of preparation contains active substance of the present invention and sterile carrier.According to carrier and concentration, this chemical compound can be suspended or dissolving.The preparation of solution is normally by being dissolved in active substance in a kind of carrier filter-sterilized before it is packed into a kind of suitable bottle or ampoule, sealing then.For example a kind of local anesthetic of adjuvant, antiseptic and buffer agent also can be dissolved in this carrier.In order to improve its stability, can be after the bottle of packing into that this compositions is freezing, and under vacuum, water is removed.
Chinese medicine composition of the present invention, when being prepared into medicament, optionally add suitable medicine acceptable carrier, described medicine acceptable carrier is selected from: mannitol, sorbitol, sodium pyrosulfite, sodium sulfite, sodium thiosulfate, cysteine hydrochloride, TGA, methionine, vitamin C, the EDTA disodium, EDTA calcium sodium, the alkali-metal carbonate of monovalence, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulphuric acid, phosphoric acid, aminoacid, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivative, cellulose and derivant thereof, alginate, gelatin, polyvinylpyrrolidone, glycerol, soil temperature 80, agar, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, beta-schardinger dextrin-, the phospholipid material, Kaolin, Pulvis Talci, calcium stearate, magnesium stearate etc.
Compositions of the present invention is determined usage and dosage according to patient's situation in use, but obeys every day three times, each 1-20 agent, as: 1-20 bag or grain or sheet.
The present composition is to be prepared from through following method, and concrete steps are as follows:
(1) Radix Bupleuri, Rhizoma Chuanxiong alcohol extraction, extracting solution concentrate concentrated solution;
(2) Radix Scutellariae water is carried acid precipitation and is got Radix Scutellariae extract;
(3) Radix Paeoniae Alba, Radix Rhapontici, Medulla Tetrapanacis, Semen Vaccariae water extract-alcohol precipitation, extracting solution concentrate concentrated solution;
(4) concentrated solution and the concentrate drying after the above-mentioned extracted twice adds Radix Scutellariae extract, promptly gets pharmaceutically active substance, and this active substance mixes with the medicine acceptable carrier, makes pharmaceutical preparations composition according to the galenic pharmacy routine techniques.
The preparation method of the preferred present composition is as follows:
(1) alcohol extraction of the 30-95% that doubly measures with 6-10 of Radix Bupleuri, Rhizoma Chuanxiong is 1-3 time, and each 1-3 hour, merge extractive liquid, also reclaimed alcohol, concentrated solution;
(2) Radix Scutellariae decocts 1-3 time with 6-10 times of water gaging, and each 1-3 hour, merging filtrate, transfer pH1.5～3.0 with dilute hydrochloric acid, more than 0.5 hour, leave standstill more than 12 hours in 50-95 ℃ of insulation, filtration or centrifugal precipitates with ethanol, is washed to pH4～8 dryings, gets Radix Scutellariae extract;
(3) Radix Paeoniae Alba, Radix Rhapontici, Medulla Tetrapanacis, Semen Vaccariae extract 1-3 time with 6-10 times of water gaging, and each 1-3 hour, merge extractive liquid,, 50-100 ℃ is concentrated into relative density and reaches 1.05～1.20, adds ethanol and makes and contain the alcohol amount and reach 50-80%, leaves standstill, filter, get supernatant recovery ethanol and get concentrated solution;
(4) above concentrated solution is merged, concentrate and receive cream, add Radix Scutellariae extract, stirring promptly gets pharmaceutically active substance, and this active substance mixes with the medicine acceptable carrier, makes pharmaceutical preparations composition according to the galenic pharmacy routine techniques;
Wherein the described alcohol of step (1) (3) is selected from: methanol, ethanol, propanol, butanols, n-butyl alcohol or amylalcohol.
The preparation method of the further preferred present composition is as follows:
(1) the 50-80% ethanol extraction doubly measured with 8-10 of Radix Bupleuri, Rhizoma Chuanxiong is 1-3 time, and each 1-3 hour, merge extractive liquid, also reclaimed ethanol, concentrated solution;
(2) Radix Scutellariae decocts 1-3 time with 8-10 times of water gaging, and each 1-3 hour, merging filtrate was transferred pH1.5～2.5 with dilute hydrochloric acid, in 70-85 ℃ of insulation 0.5-3 hour, leave standstill more than 12 hours filtration or centrifugal under the room temperature, precipitate with ethanol, be washed to pH5～7, drying gets Radix Scutellariae extract;
(3) Radix Paeoniae Alba, Radix Rhapontici, Medulla Tetrapanacis, Semen Vaccariae extract 1-3 time with 8-10 times of water gaging, and each 1-3 hour, merge extractive liquid,, 60-90 ℃ is concentrated into relative density and reaches 1.05～1.20, adds ethanol and makes and contain the alcohol amount and reach 65%, leaves standstill, filter, get supernatant recovery ethanol and get concentrated solution;
(4) above concentrated solution merges the concentrated cream of receiving of continuation, adds Radix Scutellariae extract, and stirring promptly gets pharmaceutically active substance, and this active substance mixes with the medicine acceptable carrier, makes pharmaceutical preparation according to the galenic pharmacy routine techniques.
The preparation method of the most preferred present composition is as follows:
(1) Radix Bupleuri, Rhizoma Chuanxiong are with 70% ethanol extraction of 8 times of amounts 2 times, and the 1st time 2 hours, the 2nd time 1 hour, merge extractive liquid, also reclaimed ethanol, concentrated solution;
(2) Radix Scutellariae decocts 2 times with 8 times of water gagings, and each 1 hour, merging filtrate was transferred pH1.5～2.0 with dilute hydrochloric acid, in 80 ℃ of insulations 1 hour, leaves standstill under the room temperature 24 hours, filters, and precipitates with ethanol, is washed to pH5～5-7, and drying gets Radix Scutellariae extract;
(3) Radix Paeoniae Alba, Radix Rhapontici, Medulla Tetrapanacis, Semen Vaccariae extract 2 times with 8 times of water gagings, and the 1st time 1.5 hours, the 2nd time 1 hour, secondary raffinate merges, and 70-80 ℃ is concentrated into relative density and reaches 1.05～1.20, adds ethanol and makes and contain the alcohol amount and reach 65%, leave standstill, filter, get supernatant recovery ethanol and get concentrated solution;
(4) above concentrated solution merges the concentrated cream of receiving of continuation, adds Radix Scutellariae extract, and stirring promptly gets pharmaceutically active substance, and this active substance mixes with the medicine acceptable carrier, makes pharmaceutical preparation according to the galenic pharmacy routine techniques.
Further specify the therapeutic effect of pharmaceutical composition of the present invention by following experiment.
By animal experiment study pharmacodynamics of the present invention, observe the influence of Lactogenic medicine of the present invention to female Mus lactation amount, lactotropin content, 5-hydroxy tryptamine content, mammary gland tissue.
One. materials and methods
1.1 laboratory animal
SPF level Wister rat, quantity is male: female=1: 4, body weight 250～300g.
1.2 be subjected to reagent
The extractum (pharmaceutically active substance of embodiment 1 method preparation) that does not add adjuvant after the Lactogenic medicine employing extraction process.Positive control drug: the lactogenesis granule of enriching blood.Produce the accurate word Z20000126 of traditional Chinese medicines, lot number: 20081003 by Jiuzhitang Co., Ltd..Levodopa is the sigma product.Rat blood serum prolactin antagonist detection kit, rat tissue's 5-hydroxy tryptamine detection kit are provided by ADL company; Reagent: formaldehyde, 95% ethanol, glacial acetic acid, n-butyl alcohol, concentrated hydrochloric acid etc. are homemade analytical pure.
1.3 experimental technique
To raise with cage in 1: 4 ratio without male rat and female rats pregnant, that produce, natural mating is become pregnant, adopt the cloudy bolt inspection technique of pallet to screen pregnant Mus, the single cage of the Mus of will becoming pregnant is raised as experiment, and be divided into 5 groups, be respectively dosage group, lactagogue high dose group, positive controls in model group, lactagogue low dose group, the lactagogue, every group of 10 Mus of becoming pregnant.
The female Mus of becoming pregnant divides the puerperium that every nest filial mice is adjusted into 8 without exception.Except that normal group, other are respectively organized 2 and give female Mus lumbar injection levodopa 2mg/kg, continuous 7 days every day next day from childbirth.Each modeling group began to observe 14 days to being subjected to reagent in modeling the same day.
1.4 detection index
1.4.1 lactation amount is measured
A. after single lactation amount filial mice and female Mus isolate 5h, press the filial mice abdominal part with after discharging urine with light finger, the full nest body weight of weighing is sent filial mice back to the suckling at one's side of female Mus then, sucking the breast claims the filial mice body weight behind the 1h once more, to be reset to full nest filial mice single lactation amount than the body that increases before sucking the breast.
B. total lactation amount with the hungry 4h of full nest filial mice after, make female Mus suckling 15h, before and after suckling, divide another name filial mice body weight, represent female Mus lactation amount on the one with its body weight difference, accumulative total 14d total amount is as total lactation amount.
1.4.2 biochemical indicator
After experiment finished, postcava was got blood, and centrifuging and taking serum is standby in-20 ℃ of preservations.
A. serum prolactin (PRL) is measured and is used the ELISA method, presses the test kit description and measures PRL content.
B. hypothalamus 5-hydroxy tryptamine (5-HT) is measured the hypothalamus 0.1g that accurate weighing is drawn materials, and the acid n-butyl alcohol (concentrated hydrochloric acid that adds 0.85ml in the 500ml n-butyl alcohol) that adds 2ml carries out tissue homogenate; The 5min that vibrates again after the homogenate, the centrifugal 10min of 3000r/min gets supernatant in order to measuring.Use the ELISA method, measure female Mus hypothalamus 5-HT content by the test kit description.
1.4.3 mammary gland tissue pathology morphological observation
Its mammary gland is got in dissection, is fixed in the tissue for preparing immediately and preserves in the liquid (10% formaldehyde, 5% glacial acetic acid, 85% water), conventional section, HE dyeing, tissues observed morphological change.
Two. result and discussion
2.1 each group is to female Mus lactation amount influence
Each group sees Table 1 to the measurement result of female Mus lactation amount.In each group of administration, the basic, normal, high dosage group of lactagogue is compared with model group after the modeling, and single lactation amount and total lactation amount all are significantly increased.And, the basic, normal, high dosage group of lactagogue tool dose-effect relationship.
Each group of table 1 is to female Mus lactation amount influence
| Group | Dosage (g/kg) | Single lactation amount (g) | Total lactation amount (g) |
| Model group | - | 0.34±0.11 | 134.98±48.60 |
| The lactagogue low dose group | 1.23 | 0.45±0.15 | 147.68±54.11 |
| Dosage in the lactagogue | 2.47 | 0.53±0.17* | 151.29±34.54 |
| The lactagogue high dose group | 3.69 | 0.59±0.24** | 174.24±22.49* |
| Positive controls | 1.87 | 0.64±0.15** | 170.45±44.17* |
* represent to compare p＜0.05 with model group; * represents to compare with model group, p＜0.01
2.2 each group is to the influence of female Mus lactotropin and 5-hydroxy tryptamine content
Prolactin antagonist is multi-functional hormone, is produced by hypophysis cerebri, can promote mammoplasia, growth and emulsion to form.5-hydroxy tryptamine can promote the secretion of lactotropin as a kind of central nervous system's mediator.As can be known, each administration group lactotropin content is compared with model group with group 5-hydroxy tryptamine content after the modeling all increase from the listed result of table 2, and wherein high dose group has remarkable increase.The basic, normal, high dosage group of lactagogue tool dose-effect relationship.
Each group of table 2 is to the influence of female Mus lactotropin and 5-hydroxy tryptamine content
* represent to compare p＜0.05 with model group; * represents to compare with model group, p＜0.01
2.3 each group influences the morphology of mammary gland tissue pathology
From each group mammary gland tissue pathology morphological observation result is shown, each group of administration can be urged into female molluscum contagiosum gland hypertrophy age of sucking, makes mammary gland tissue be height lactogenic state.Observed result sees Table 3.
Each group of table 3 influences the morphology of mammary gland tissue pathology
Above effect experiment result shows that Lactogenic medicine of the present invention can significantly increase the female Mus lactation amount of hypogalactia, can obviously increase hypogalactia animal serum lactotropin content and hypothalamus 5-hydroxy tryptamine content, makes mammary gland tissue be height lactogenic state.
Compositions among cited all embodiment of the present invention has the 1 essentially identical effect with embodiment.
Compositions of the present invention is lactogenic and safe and reliable effectively, taking convenience, and adaptability and compliance are good; The fully natural green tcm product has reduced the hazardness that baby clothes are used; Said composition is also regulated the postpartum women deficient qi and blood, and health invigorating and immunity help the physical and mental health of parent, and compositions of the present invention also has good stability, few side effects, long shelf-life, characteristics such as therapeutic effect is remarkable.Simultaneously, preparation method of the present invention is simple, is fit to production, the extraction ratio height; Composition prescription is a conventional Chinese medicine in this invention, avoids the use of rare Chinese medicine and animal drugs, has reduced production cost, benefits extensive patients, is fit to promote.
The specific embodiment:
Explaining content of the present invention by the following specific embodiment, is not the further qualification to protection domain of the present invention.
Embodiment 1, pharmaceutical composition of the present invention
Radix Bupleuri 10g, Radix Paeoniae Alba 10g, Radix Scutellariae 6g, Radix Rhapontici 10g,
Medulla Tetrapanacis 6g, Rhizoma Chuanxiong 10g, Semen Vaccariae 15g
The above-mentioned raw materials medicine is processed into through following method:
(1) Radix Bupleuri, Rhizoma Chuanxiong are with 70% ethanol extraction of 8 times of amounts 2 times, and the 1st time 2 hours, the 2nd time 1 hour, merge extractive liquid, also reclaimed ethanol, concentrated solution;
(2) Radix Scutellariae decocts 2 times with 8 times of water gagings, and each 1 hour, merging filtrate was transferred pH1.5～2.0 with dilute hydrochloric acid, in 80 ℃ of insulations 1 hour, leaves standstill under the room temperature 24 hours, filters, and precipitates with ethanol, is washed to pH5～6, and drying gets Radix Scutellariae extract;
(3) Radix Paeoniae Alba, Radix Rhapontici, Medulla Tetrapanacis, Semen Vaccariae extract 2 times with 8 times of water gagings, and the 1st time 1.5 hours, the 2nd time 1 hour, secondary raffinate merges, and 80 ℃ are concentrated into relative density and reach 1.05～1.20, adds ethanol and makes and contain the alcohol amount and reach 65%, leave standstill, filter, get supernatant recovery ethanol and get concentrated solution;
(4) above concentrated solution merges the concentrated cream of receiving of continuation, adds Radix Scutellariae extract, and stirring promptly gets pharmaceutically active substance, and this active substance mixes with the medicine acceptable carrier, makes pharmaceutical preparation according to the galenic pharmacy routine techniques.
Embodiment 2, pharmaceutical composition of the present invention
Radix Bupleuri 3g, Radix Paeoniae Alba 3g, Radix Scutellariae 2g, Radix Rhapontici 3g,
Medulla Tetrapanacis 2g, Rhizoma Chuanxiong 3g, Semen Vaccariae 5g
The above-mentioned raw materials medicine is processed into through following method:
(1) Radix Bupleuri, Rhizoma Chuanxiong are with 50% ethanol extraction of 8 times of amounts 2 times, and each 1 hour, merge extractive liquid, also reclaimed ethanol, concentrated solution;
(2) Radix Scutellariae decocts 2 times with 8 times of water gagings, and each 1 hour, merging filtrate was transferred pH1.5～2.0 with dilute hydrochloric acid, in 80 ℃ of insulations 1 hour, leaves standstill under the room temperature 24 hours, filters, and precipitates with ethanol, is washed to pH5～6, and drying gets Radix Scutellariae extract;
(3) Radix Paeoniae Alba, Radix Rhapontici, Medulla Tetrapanacis, Semen Vaccariae are extracted 2 times with 8 times of water gagings, and each 1 hour, secondary raffinate merged, and 80 ℃ are concentrated into relative density and reach 1.05～1.20, add ethanol and make and contain the alcohol amount and reach 65%, leave standstill, and filter, and get supernatant and reclaim ethanol and get concentrated solution;
(4) above concentrated solution merges the concentrated cream of receiving of continuation, adds Radix Scutellariae extract, and stirring promptly gets pharmaceutically active substance, and this active substance mixes with the medicine acceptable carrier, makes pharmaceutical preparation according to the galenic pharmacy routine techniques.
Embodiment 3, pharmaceutical composition of the present invention
Radix Bupleuri 30g, Radix Paeoniae Alba 30g, Radix Scutellariae 18g, Radix Rhapontici 30g,
Medulla Tetrapanacis 18g, Rhizoma Chuanxiong 30g, Semen Vaccariae 45g.
The above-mentioned raw materials medicine is processed into through following method:
(1) Radix Bupleuri, Rhizoma Chuanxiong are with 80% ethanol extraction of 10 times of amounts 3 times, and each 3 hours, merge extractive liquid, also reclaimed ethanol, concentrated solution;
(2) Radix Scutellariae decocts 3 times with 10 times of water gagings, and each 3 hours, merging filtrate was transferred pH1.5～2.0 with dilute hydrochloric acid, in 80 ℃ of insulations 1 hour, leaves standstill under the room temperature 24 hours, filters, and precipitates with ethanol, is washed to pH5～6, and drying gets Radix Scutellariae extract;
(3) Radix Paeoniae Alba, Radix Rhapontici, Medulla Tetrapanacis, Semen Vaccariae extract 2 times with 10 times of water gagings, and each 3 hours, secondary raffinate merged, 80 ℃ are concentrated into relative density and reach 1.05～1.20, add ethanol and make and contain the alcohol amount and reach 65%, leave standstill, filter, get supernatant recovery ethanol and get concentrated solution;
(4) above concentrated solution merges the concentrated cream of receiving of continuation, adds Radix Scutellariae extract, and stirring promptly gets pharmaceutically active substance, and this active substance mixes with the medicine acceptable carrier, makes pharmaceutical preparation according to the galenic pharmacy routine techniques.
Embodiment 4, pharmaceutical composition of the present invention
Radix Bupleuri 5g, Radix Paeoniae Alba 5g, Radix Scutellariae 3g, Radix Rhapontici 5g,
Medulla Tetrapanacis 3g, Rhizoma Chuanxiong 5g, Semen Vaccariae 7.5g.
The above-mentioned raw materials medicine is processed into through following method:
(1) Radix Bupleuri, Rhizoma Chuanxiong are with 70% methanol extraction of 8 times of amounts 2 times, and the 1st time 2 hours, the 2nd time 1 hour, merge extractive liquid, also reclaimed ethanol, concentrated solution;
(2) Radix Scutellariae decocts 2 times with 8 times of water gagings, and each 1 hour, merging filtrate was transferred pH1.5～2.0 with dilute hydrochloric acid, in 80 ℃ of insulations 1 hour, leaves standstill under the room temperature 24 hours, filters, and precipitates with ethanol, is washed to pH5～6, and drying gets Radix Scutellariae extract;
(3) Radix Paeoniae Alba, Radix Rhapontici, Medulla Tetrapanacis, Semen Vaccariae extract 2 times with 8 times of water gagings, and the 1st time 1.5 hours, the 2nd time 1 hour, secondary raffinate merges, and 80 ℃ are concentrated into relative density and reach 1.05～1.20, adds ethanol and makes and contain the alcohol amount and reach 65%, leave standstill, filter, get supernatant recovery ethanol and get concentrated solution;
(4) above concentrated solution merges the concentrated cream of receiving of continuation, adds Radix Scutellariae extract, and stirring promptly gets pharmaceutically active substance, and this active substance mixes with the medicine acceptable carrier, makes pharmaceutical preparation according to the galenic pharmacy routine techniques.
Embodiment 5, pharmaceutical composition of the present invention
Radix Bupleuri 20g, Radix Paeoniae Alba 20g, Radix Scutellariae 12g, Radix Rhapontici 20g,
Medulla Tetrapanacis 12g, Rhizoma Chuanxiong 20g, Semen Vaccariae 30g.
The above-mentioned raw materials medicine is processed into through following method:
(1) Radix Bupleuri, Rhizoma Chuanxiong are with 30% alcohol extraction of 6 times of amounts 3 times, and each 3 hours, merge extractive liquid, also reclaimed alcohol, concentrated solution;
(2) Radix Scutellariae decocts 1 time with 6 times of water gagings, and each 1 hour, merging filtrate was transferred pH1.5～2.0 with dilute hydrochloric acid, in 80 ℃ of insulations 1 hour, leaves standstill 24 hours, filters, and precipitates with ethanol, is washed to pH5～6, and drying gets Radix Scutellariae extract;
(3) Radix Paeoniae Alba, Radix Rhapontici, Medulla Tetrapanacis, Semen Vaccariae are extracted 3 times with 6 times of water gagings, and each 2 hours, merge extractive liquid,, 80 ℃ are concentrated into relative density and reach 1.05～1.20, add ethanol and make and contain the alcohol amount and reach 50%, leave standstill, and filter, and get supernatant and reclaim ethanol and get concentrated solution;
(4) above concentrated solution is merged, concentrate and receive cream, add Radix Scutellariae extract, stirring promptly gets pharmaceutically active substance, and this active substance mixes with the medicine acceptable carrier, makes pharmaceutical preparation according to the galenic pharmacy routine techniques.
Embodiment 6, pharmaceutical composition of the present invention
10 parts of Radix Bupleuri, 10 parts of the Radix Paeoniae Albas, 6 parts of Radix Scutellariaes, 10 parts of Radix Rhapontici,
6 parts of Medulla Tetrapanaciss, 10 parts of Rhizoma Chuanxiongs, 15 parts of Semen Vaccariae.
(1) Radix Bupleuri, Rhizoma Chuanxiong are with 90% alcohol extraction of 8 times of amounts 2 times, and each 2 hours, merge extractive liquid, also reclaimed alcohol, concentrated solution;
(2) Radix Scutellariae decocts 2 times with 8 times of water gagings, and each 2 hours, merging filtrate was transferred pH1.5 with dilute hydrochloric acid,, leaves standstill more than 12 hours more than 0.5 hour in 50 ℃ of insulations, and filtration or centrifugal precipitates with ethanol, is washed to the pH4 drying, gets Radix Scutellariae extract;
(3) Radix Paeoniae Alba, Radix Rhapontici, Medulla Tetrapanacis, Semen Vaccariae are extracted 2 times with 8 times of water gagings, and each 2 hours, merge extractive liquid,, 50 ℃ are concentrated into relative density and reach 1.05～1.20, add ethanol and make and contain the alcohol amount and reach 50%, leave standstill, and filter, and get supernatant and reclaim ethanol and get concentrated solution;
(4) above concentrated solution is merged, concentrate and receive cream, add Radix Scutellariae extract, stirring promptly gets pharmaceutically active substance, and this active substance mixes with the medicine acceptable carrier, makes pharmaceutical preparation according to the galenic pharmacy routine techniques;
Embodiment 7, pharmaceutical composition of the present invention
10 parts of Radix Bupleuri, 10 parts of the Radix Paeoniae Albas, 6 parts of Radix Scutellariaes, 10 parts of Radix Rhapontici,
6 parts of Medulla Tetrapanaciss, 10 parts of Rhizoma Chuanxiongs, 15 parts of Semen Vaccariae.
(1) Radix Bupleuri, Rhizoma Chuanxiong are with 90% alcohol extraction of 8 times of amounts 2 times, and each 2 hours, merge extractive liquid, also reclaimed alcohol, concentrated solution;
(2) Radix Scutellariae decocts 2 times with 8 times of water gagings, and each 2 hours, merging filtrate was transferred pH3.0 with dilute hydrochloric acid,, leaves standstill more than 12 hours more than 0.5 hour in 95 ℃ of insulations, and filtration or centrifugal precipitates with ethanol, is washed to the pH8 drying, gets Radix Scutellariae extract;
(3) Radix Paeoniae Alba, Radix Rhapontici, Medulla Tetrapanacis, Semen Vaccariae are extracted 2 times with 8 times of water gagings, and each 2 hours, merge extractive liquid,, 100 ℃ are concentrated into relative density and reach 1.05～1.20, add ethanol and make and contain the alcohol amount and reach 80%, leave standstill, and filter, and get supernatant and reclaim ethanol and get concentrated solution;
(4) above concentrated solution is merged, concentrate and receive cream, add Radix Scutellariae extract, stirring promptly gets pharmaceutically active substance, and this active substance mixes with the medicine acceptable carrier, makes pharmaceutical preparation according to the galenic pharmacy routine techniques;
Embodiment 8, pharmaceutical composition of the present invention
10 parts of Radix Bupleuri, 10 parts of the Radix Paeoniae Albas, 6 parts of Radix Scutellariaes, 10 parts of Radix Rhapontici,
6 parts of Medulla Tetrapanaciss, 10 parts of Rhizoma Chuanxiongs, 15 parts of Semen Vaccariae.
(1) Radix Bupleuri, Rhizoma Chuanxiong are with 50% ethanol extraction of 8 times of amounts 1 time, and each 1 hour, merge extractive liquid, also reclaimed ethanol, concentrated solution;
(2) Radix Scutellariae decocts 1 time with 8 times of water gagings, and each 1 hour, merging filtrate was transferred pH1.5 with dilute hydrochloric acid, in 70 ℃ of insulations 0.5 hour, leaves standstill under the room temperature more than 12 hours, and filtration or centrifugal precipitates with ethanol, is washed to pH5, and drying gets Radix Scutellariae extract;
(3) Radix Paeoniae Alba, Radix Rhapontici, Medulla Tetrapanacis, Semen Vaccariae are extracted 1 time with 8 times of water gagings, and each 1 hour, merge extractive liquid,, 60 ℃ are concentrated into relative density and reach 1.05～1.20, add ethanol and make and contain the alcohol amount and reach 65%, leave standstill, and filter, and get supernatant and reclaim ethanol and get concentrated solution;
(4) above concentrated solution merges the concentrated cream of receiving of continuation, adds Radix Scutellariae extract, and stirring promptly gets pharmaceutically active substance, and this active substance mixes with the medicine acceptable carrier, makes pharmaceutical preparation according to the galenic pharmacy routine techniques.
Embodiment 9, pharmaceutical composition of the present invention
10 parts of Radix Bupleuri, 10 parts of the Radix Paeoniae Albas, 6 parts of Radix Scutellariaes, 10 parts of Radix Rhapontici,
6 parts of Medulla Tetrapanaciss, 10 parts of Rhizoma Chuanxiongs, 15 parts of Semen Vaccariae.
(1) Radix Bupleuri, Rhizoma Chuanxiong are with 80% ethanol extraction of 10 times of amounts 3 times, and each 3 hours, merge extractive liquid, also reclaimed ethanol, concentrated solution;
(2) Radix Scutellariae decocts 3 times with 10 times of water gagings, and each 3 hours, merging filtrate was transferred pH2.5 with dilute hydrochloric acid, in 85 ℃ of insulations 3 hours, leaves standstill under the room temperature more than 12 hours, and filtration or centrifugal precipitates with ethanol, is washed to pH7, and drying gets Radix Scutellariae extract;
(3) Radix Paeoniae Alba, Radix Rhapontici, Medulla Tetrapanacis, Semen Vaccariae are extracted 3 times with 10 times of water gagings, and each 3 hours, merge extractive liquid,, 90 ℃ are concentrated into relative density and reach 1.05～1.20, add ethanol and make and contain the alcohol amount and reach 65%, leave standstill, and filter, and get supernatant and reclaim ethanol and get concentrated solution;
(4) above concentrated solution merges the concentrated cream of receiving of continuation, adds Radix Scutellariae extract, and stirring promptly gets pharmaceutically active substance, and this active substance mixes with the medicine acceptable carrier, makes pharmaceutical preparation according to the galenic pharmacy routine techniques.
Embodiment 10, granule
Get any one pharmaceutically active substance 100g of embodiment 1-5, add the dextrin of 1.5 times of amounts, 0.5% sucrose, 1.5% microcrystalline Cellulose is made soft material with an amount of dissolve with ethanol, granulates, and 60 ℃ of forced air dryings are granulated, and granulate promptly gets granule.
Embodiment 11, drop pill
Get any one pharmaceutically active substance 100g of embodiment 1-5, add the Polyethylene Glycol of 1000g, mix homogeneously, fusion, last drop pill machine is made drop pill.
Embodiment 12, oral cavity disintegration tablet
Get any one pharmaceutically active substance 100g of embodiment 1-5, add 5% polyvinylpolypyrrolidone, 0.1% magnesium stearate, 50% microcrystalline Cellulose, make soft material with an amount of alcoholic solution, granulate, 60 ℃ of forced air dryings are granulated, granulate, compacting promptly gets oral cavity disintegration tablet in flakes.
Embodiment 13, injectable powder
Get any pharmaceutically active substance 0.5g of embodiment 1-5, glucose 4.5g, sodium thiosulfate 0.9g and distilled water 1ml, behind the said components mix homogeneously, lyophilization, 500 of packing promptly get injectable powder.
Embodiment 14, capsule
Get any pharmaceutically active substance 100g of embodiment 1-5, add equivalent starch, sucrose and magnesium stearate are granulated, and incapsulate, and promptly get capsule.
Embodiment 15, tablet
Get any pharmaceutically active substance 100g of embodiment 1-5, with starch, sodium carboxymethyl cellulose, Pulvis Talci mix homogeneously are granulated, and tabletting promptly gets tablet.
Embodiment 16, oral liquid
Get any pharmaceutically active substance 2g of embodiment 1-9, with syrup 4g, be dissolved in the pure water of 100ml, homogenizing filters, through high-temperature short-time sterilization (135 ℃, 4s).Sterile filling, packing.Make oral liquid.
Group component in the foregoing description and the description scope can enlarge or reduce in scale simultaneously according to producing needs.
Claims (10)
1. the pharmaceutical composition with galgctogogue action is characterized in that, described compositions is processed into by the raw material of following weight parts:
Radix Bupleuri 3-30 part, Radix Paeoniae Alba 3-30 part, Radix Scutellariae 2-18 part, Radix Rhapontici 3-30 part,
Medulla Tetrapanacis 2-18 part, Rhizoma Chuanxiong 3-30 part, Semen Vaccariae 5-45 part.
2. compositions according to claim 1 is characterized in that, described compositions is processed into by the raw material of following weight parts:
Radix Bupleuri 5-20 part, Radix Paeoniae Alba 5-20 part, Radix Scutellariae 3-12 part, Radix Rhapontici 5-20 part,
Medulla Tetrapanacis 3-12 part, Rhizoma Chuanxiong 5-20 part, Semen Vaccariae 7.5-30 part.
3. compositions according to claim 2 is characterized in that, described compositions is processed into by the raw material of following weight parts:
10 parts of Radix Bupleuri, 10 parts of the Radix Paeoniae Albas, 6 parts of Radix Scutellariaes, 10 parts of Radix Rhapontici,
6 parts of Medulla Tetrapanaciss, 10 parts of Rhizoma Chuanxiongs, 15 parts of Semen Vaccariae.
4. according to described any one compositions of claim 1-3, wherein contain pharmaceutically acceptable carrier.
5. according to described any one compositions of claim 1-3, be any pharmaceutically useful dosage form.
6. the described preparation of compositions method of claim 1 is characterized in that, may further comprise the steps:
(1) Radix Bupleuri, Rhizoma Chuanxiong alcohol extraction, extracting solution concentrate concentrated solution;
(2) Radix Scutellariae water is carried acid precipitation and is got Radix Scutellariae extract;
(3) Radix Paeoniae Alba, Radix Rhapontici, Medulla Tetrapanacis, Semen Vaccariae water extract-alcohol precipitation, extracting solution concentrate concentrated solution;
(4) concentrated solution and the concentrate drying after the above-mentioned extracted twice adds Radix Scutellariae extract, promptly gets pharmaceutically active substance, and this active substance mixes with the medicine acceptable carrier, makes pharmaceutical preparation according to the galenic pharmacy routine techniques.
7. the described preparation of compositions method of claim 6 is characterized in that, may further comprise the steps:
(1) alcohol extraction of the 30-95% that doubly measures with 6-10 of Radix Bupleuri, Rhizoma Chuanxiong is 1-3 time, and each 1-3 hour, merge extractive liquid, also reclaimed alcohol, concentrated solution;
(2) Radix Scutellariae decocts 1-3 time with 6-10 times of water gaging, and each 1-3 hour, merging filtrate, transfer pH1.5～3.0 with dilute hydrochloric acid, more than 0.5 hour, leave standstill more than 12 hours in 50-95 ℃ of insulation, filtration or centrifugal precipitates with ethanol, is washed to pH4～8 dryings, gets Radix Scutellariae extract;
(3) Radix Paeoniae Alba, Radix Rhapontici, Medulla Tetrapanacis, Semen Vaccariae extract 1-3 time with 6-10 times of water gaging, and each 1-3 hour, merge extractive liquid,, 50-100 ℃ is concentrated into relative density and reaches 1.05～1.20, adds ethanol and makes and contain the alcohol amount and reach 50-80%, leaves standstill, filter, get supernatant recovery ethanol and get concentrated solution;
(4) above concentrated solution is merged, concentrate and receive cream, add Radix Scutellariae extract, stirring promptly gets pharmaceutically active substance, and this active substance mixes with the medicine acceptable carrier, makes pharmaceutical preparation according to the galenic pharmacy routine techniques;
Wherein the described alcohol of step (1) is selected from: methanol, ethanol, propanol, butanols, n-butyl alcohol or amylalcohol.
8. the described preparation of compositions method of claim 6 is characterized in that, may further comprise the steps:
(1) the 50-80% ethanol extraction doubly measured with 8-10 of Radix Bupleuri, Rhizoma Chuanxiong is 1-3 time, and each 1-3 hour, merge extractive liquid, also reclaimed ethanol, concentrated solution;
(2) Radix Scutellariae decocts 1-3 time with 8-10 times of water gaging, and each 1-3 hour, merging filtrate was transferred pH1.5～2.5 with dilute hydrochloric acid, in 70-85 ℃ of insulation 0.5-3 hour, leave standstill more than 12 hours filtration or centrifugal under the room temperature, precipitate with ethanol, be washed to pH5～7, drying gets Radix Scutellariae extract;
(3) Radix Paeoniae Alba, Radix Rhapontici, Medulla Tetrapanacis, Semen Vaccariae extract 1-3 time with 8-10 times of water gaging, and each 1-3 hour, merge extractive liquid,, 60-90 ℃ is concentrated into relative density and reaches 1.05～1.20, adds ethanol and makes and contain the alcohol amount and reach 65%, leaves standstill, filter, get supernatant recovery ethanol and get concentrated solution;
(4) above concentrated solution merges the concentrated cream of receiving of continuation, adds Radix Scutellariae extract, and stirring promptly gets pharmaceutically active substance, and this active substance mixes with the medicine acceptable carrier, makes pharmaceutical preparation according to the galenic pharmacy routine techniques.
9. the described preparation of compositions method of claim 6 is characterized in that, may further comprise the steps:
(1) Radix Bupleuri, Rhizoma Chuanxiong are with 70% ethanol extraction of 8 times of amounts 2 times, and the 1st time 2 hours, the 2nd time 1 hour, merge extractive liquid, also reclaimed ethanol, concentrated solution;
(2) Radix Scutellariae decocts 2 times with 8 times of water gagings, and each 1 hour, merging filtrate was transferred pH1.5～2.0 with dilute hydrochloric acid, in 80 ℃ of insulations 1 hour, leaves standstill under the room temperature 24 hours, filters, and precipitates with ethanol, is washed to pH5～5-7, and drying gets Radix Scutellariae extract;
(3) Radix Paeoniae Alba, Radix Rhapontici, Medulla Tetrapanacis, Semen Vaccariae extract 2 times with 8 times of water gagings, and the 1st time 1.5 hours, the 2nd time 1 hour, secondary raffinate merges, and 70-80 ℃ is concentrated into relative density and reaches 1.05～1.20, adds ethanol and makes and contain the alcohol amount and reach 65%, leave standstill, filter, get supernatant recovery ethanol and get concentrated solution;
(4) above concentrated solution merges the concentrated cream of receiving of continuation, adds Radix Scutellariae extract, and stirring promptly gets pharmaceutically active substance, and this active substance mixes with the medicine acceptable carrier, makes pharmaceutical preparation according to the galenic pharmacy routine techniques.
10. the application of described any one compositions of claim 1-3 in the medicine of preparation galgctogogue action.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910228130XA CN102048841B (en) | 2009-11-10 | 2009-11-10 | Lactogenic traditional Chinese medicine composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910228130XA CN102048841B (en) | 2009-11-10 | 2009-11-10 | Lactogenic traditional Chinese medicine composition and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102048841A true CN102048841A (en) | 2011-05-11 |
| CN102048841B CN102048841B (en) | 2013-12-04 |
Family
ID=43953858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910228130XA Expired - Fee Related CN102048841B (en) | 2009-11-10 | 2009-11-10 | Lactogenic traditional Chinese medicine composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102048841B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102399252A (en) * | 2011-12-15 | 2012-04-04 | 成都普思生物科技有限公司 | Preparation method for cowherb seed flavonoid glycoside monomer |
| CN104922522A (en) * | 2015-06-25 | 2015-09-23 | 康莉 | Traditional Chinese medicine composition for treating liver-qi invasion type postpartum hypogalactia |
| CN106109905A (en) * | 2016-08-30 | 2016-11-16 | 瑞普（天津）生物药业有限公司 | A kind of Chinese medicine composition of lactogenic |
| CN114886030A (en) * | 2022-06-02 | 2022-08-12 | 湖南农业大学 | Compound Chinese herbal medicine feed additive for sows and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1416861A (en) * | 2002-11-04 | 2003-05-14 | 漳洲片仔癀药业股份有限公司 | Pharmaceutical composition with lactation function and preparation method thereof |
| CN1857512A (en) * | 2006-03-10 | 2006-11-08 | 辽宁好护士药业（集团）有限责任公司 | Chinese medicine for treating puerperal hypogalactia and its preparing method |
-
2009
- 2009-11-10 CN CN200910228130XA patent/CN102048841B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1416861A (en) * | 2002-11-04 | 2003-05-14 | 漳洲片仔癀药业股份有限公司 | Pharmaceutical composition with lactation function and preparation method thereof |
| CN1857512A (en) * | 2006-03-10 | 2006-11-08 | 辽宁好护士药业（集团）有限责任公司 | Chinese medicine for treating puerperal hypogalactia and its preparing method |
Non-Patent Citations (1)
| Title |
|---|
| 何军琴等: "中医对产后缺乳的认识及治疗现状", 《中国中医药信息杂志》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102399252A (en) * | 2011-12-15 | 2012-04-04 | 成都普思生物科技有限公司 | Preparation method for cowherb seed flavonoid glycoside monomer |
| CN104922522A (en) * | 2015-06-25 | 2015-09-23 | 康莉 | Traditional Chinese medicine composition for treating liver-qi invasion type postpartum hypogalactia |
| CN106109905A (en) * | 2016-08-30 | 2016-11-16 | 瑞普（天津）生物药业有限公司 | A kind of Chinese medicine composition of lactogenic |
| CN114886030A (en) * | 2022-06-02 | 2022-08-12 | 湖南农业大学 | Compound Chinese herbal medicine feed additive for sows and preparation method and application thereof |
| CN114886030B (en) * | 2022-06-02 | 2024-01-09 | 湖南农业大学 | Compound Chinese herbal medicine feed additive for sow and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102048841B (en) | 2013-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101940740B (en) | Chinese medicinal preparation for treating anemia | |
| CN100366280C (en) | Medicinal composition for treating hypertension, its preparation method and use | |
| CN102120020B (en) | Medicinal composition for treating hyperplastic diseases of breast and hysteromyoma and preparation method thereof | |
| CN102048841B (en) | Lactogenic traditional Chinese medicine composition and preparation method thereof | |
| CN102048890B (en) | Traditional Chinese medicine composition with galactagogue effect and preparation method thereof | |
| CN103585479A (en) | Blood-replenishing pill and blood-replenishing capsule for treating iron-deficiency anemia | |
| CN113713039A (en) | Traditional Chinese medicine composition for treating membranous nephropathy and application thereof | |
| CN104189349B (en) | Traditional Chinese medicine composition for treating oligomenorrhea | |
| CN100509009C (en) | Chinese medicinal preparation for treating heart cerebrovascular disease and ischemic apoplexia and making method thereof | |
| CN113952419B (en) | Pharmaceutical composition for chronic renal failure and preparation method and application thereof | |
| CN105267543A (en) | Chinese medical preparation for treating qi-stagnation and blood stasis type primary dysmenorrheal and chloasma | |
| CN102370901A (en) | Pharmaceutical composition for treating nephrosis and preparing process thereof | |
| CN112022985B (en) | Traditional Chinese medicine composition for treating children sexual precocity and preparation method and application thereof | |
| CN104257839B (en) | A kind of Chinese medicine composition with hypoglycemic protection blood vessel endothelium effect and preparation method thereof | |
| CN102485263B (en) | Medicinal composition for treating chronic cough of children and its preparation method | |
| CN105194355A (en) | Traditional Chinese medicine preparation for treating primary hypertension | |
| CN104173521B (en) | A kind of pharmaceutical composition and its preparation method giving birth to able-bodied sun | |
| CN104162090B (en) | Pharmaceutical composition and preparation method thereof | |
| CN103041288A (en) | Chinese medicinal composition for treating diabetic fatty liver and preparation process thereof | |
| CN102018940B (en) | Composition with lactogenic effect and preparation method and application thereof | |
| CN102847060A (en) | Traditional Chinese medicine composition for treating uterine myoma and preparation method thereof | |
| CN108815342B (en) | Traditional Chinese medicine composition for treating male infertility | |
| CN106038977A (en) | Polysaccharide composite, preparing method and application of polysaccharide composite | |
| CN106173604A (en) | A kind of Hyperglycemic health care compositions comprising Cortex Mori and Rhizoma Polygonati Odorati | |
| CN100371002C (en) | Chinese medicinal preparation for treating heart cerebrovascular disease and making method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Applicant after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300410 Tianjin City Hedong District of Beichen Puji Road No. 2 city of the modern Chinese Medicine Applicant before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: TIANJIN TIANSHILI PHARMACEUTICAL CO., LTD. TO: TASLY PHARMACEUTICAL GROUP CO., LTD. |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131204 Termination date: 20171110 |